The role of quantitative HBsAg in the natural history of e antigen-negative chronic hepatitis B: A Tunisian prospective study - 05/08/21
, Arwa Gueddiche a, Mehdi Ben Abdelwahed a, Firas Aissaoui a, Majda Zakhama a, Wided Bouhlel a, Asma Sriha b, Ikbel Kooli c, Om Kalthoum Sallem a, Aida Argoubi d, Loghmeri Mohamed Hichem a, Nabil Ben Chaabane a, Leila Safer aBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 6 |
| Iconographies | 4 |
| Vidéos | 0 |
| Autres | 0 |
Highlights |
• | As vaccination against hepatitis B virus (HBV) infection progresses around the world, persons presenting with chronic HBV infection (CHI) require optimal management, which is based on virological markers such as HBe serology and HBV DNA viral load. |
• | Over recent years, HBs antigen quantification (HBsAgQT) has appeared as a new marker helping to orient anti-HBV interferon treatment, and it is now recommended as a means of differentiating the CHI phases and optimizing the monitoring of infected patients. |
• | In this context, our prospective study on HBsAgQT in HBe Ag negative CHI Tunisian patients helps to determine the optimal threshold of this marker for optimal follow-up of largely predominant CHI patients. |
• | The identified decision threshold is consistent with those found in recent studies on similar patients from other geographical areas. |
Abstract |
Background/Aims |
During the natural course of Chronic Hepatitis B (CHB) infection, differentiation between inactive carrier (IC) and HBeAg negative CHB is a subject of ongoing debate. We studied the role of hepatitis B surface antigen (HBsAg) level as a means of differentiating between CHB and IC in a group of untreated chronic HBeAg-negative HBV-infected patients.
Study |
A total of 115 HBeAg negative carriers were enrolled and followed up for>12 months; 78 as inactive carriers (IC), and 37 as active carriers (AC). Among ACs, patients were categorized according to the highest rate of viral load: AC1 (n=23), active carriers with persistent HBV-DNA<20,000 IU/mL; AC2 (n=14), active carriers with HBV-DNA>20,000 IU/mL.
Results |
HBsAg levels were higher in AC compared to IC patients (1607 IU/ml vs. 225 IU/ml respectively, P=0.001). Among the AC group, the 23 AC1 cases had HBsAg levels significantly lower than the 14 AC2 patients (1756 IU/mL vs. 3327 IU/mL respectively; P<10-3). HBsAg showed weak correlation with HBV-DNA in the whole cohort (r=0.44, P<0.01). The suggested cutoff value of HBsAg titer to differentiate between the two groups was 938 IU/mL. Combined single-point quantification of HBsAg (938 IU/mL) and HBV DNA (2000 IU/mL) identified IC with 87.2% specificity and 91.7% positive predictive value.
Conclusion |
This study confirms the predictability of a one-time combined HBsAg and HBV DNA measurement for true inactive carriers requiring neither strict follow-up nor antiviral treatment.
Le texte complet de cet article est disponible en PDF.Keywords : Chronic hepatitis B e antigen–, HBV, HBsAg, Viral load
Abbreviations : HBV, CHI, HCC, HBeAg, IC, AC, CHB, ALT, AST, HBsAg, anti-HBe, y-GT, qHBsAg, AUROC
Plan
Vol 51 - N° 5
P. 464-469 - août 2021 Retour au numéro
Article précédent
- High incidence of postoperative infections after pancreaticoduodenectomy: A need for perioperative anti-infectious strategies
- P. Bortolotti, C. Delpierre, R. Le Guern, E. Kipnis, G. Lebuffe, X. Lenne, F.-R. Pruvot, S. Truant, A. Bignon, M. El Amrani
- Assessment of version 2.5 of QMAC-dRAST for rapid antimicrobial susceptibility testing with reduced sample-to-answer turnaround time and an integrated expert system
- Patrick Grohs, Simon Picard, Jean-Luc Mainardi, Isabelle Podglajen
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?